Vir生物技术股份有限公司美股招股说明书（2026年2月26日版）

17,647,059 Shares of Common Stock We are offering 17,647,059 shares of our common stock. Our common stock is listed on The Nasdaq Global Select Market (Nasdaq) under the symbol “VIR.” On February25, 2026, the lastreported sale price of our common stock on Nasdaq was $10.00per share. (1)See “Underwriting” for a description of the compensation payable to the underwriters. Investing in our common stock involves a high degree of risk. You should review carefully the risks and uncertaintiesdescribed under the heading “RISK FACTORS” beginning on pageS-10 of this prospectus supplement, and in the documentsincorporated by reference into this prospectus supplement and the accompanying base prospectus. Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved ofthese securities or passed upon the adequacy or accuracy of this prospectus supplement. Any representation to the contrary isa criminal offense. We have granted the underwriters an option for a period of 30 days to purchase up to 2,647,058 additional shares of common stockat the public offering price, less the underwriting discounts and commissions. The underwriters expect to deliver the shares against payment in New York, New York, on or about February27, 2026. EvercoreISIBarclays GoldmanSachs&Co.LLC Prospectus Supplement ABOUT THIS PROSPECTUS SUPPLEMENTCAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTSPROSPECTUS SUPPLEMENT SUMMARYRISK FACTORSUSE OF PROCEEDSMARKET AND INDUSTRY DATADIVIDEND POLICYDILUTIONMATERIAL UNITED STATES FEDERAL INCOME TAX CONSEQUENCES FOR NON-U.S. HOLDERS OF OUR COMMONSTOCKUNDERWRITINGLEGAL MATTERSEXPERTSWHERE YOU CAN FIND MORE INFORMATIONINCORPORATION OF CERTAIN INFORMATION BY REFERENCE ABOUT THIS PROSPECTUSWHERE YOU CAN FIND MORE INFORMATIONINCORPORATION OF CERTAIN INFORMATION BY REFERENCECAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS Neither we nor the underwriters have authorized anyone to provide any information or to make any representations other thanthose contained or incorporated by reference in this prospectus supplement, the accompanying prospectus or in any free writingprospectuses prepared by or on behalf of us or to which we have referred you. Neither we nor the underwriters take responsibility for, andcan provide no assurance as to the reliability of, any other information that others may give you. This prospectus supplement is an offer tosell only the shares offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. The distribution of thisprospectus supplement and the accompanying base prospectus and the offering of the common stock in certain jurisdictions may be For investors outside the United States: Neither we nor the underwriters have done anything that would permit this offering orpossession or distribution of this prospectus supplement, the accompanying prospectus or any free writing prospectus we may provide toyou in connection with this offering in any jurisdiction where action for that purpose is required, other than in the United States. You are Unless the context otherwise requires, the terms “Vir Biotechnology,” “Vir Bio,” “the Company,” “we,” “us,” “our” and similarreferences in this prospectus supplement and the accompanying prospectus refer to Vir Biotechnology, Inc. and its consolidatedsubsidiaries. ABOUT THIS PROSPECTUS SUPPLEMENT This document is in two parts. The first part is this prospectus supplement, which describes the specific terms of this offering ofshares of our common stock and also adds to and updates information contained in the accompanying base prospectus and thedocuments incorporated by reference into this prospectus supplement and the accompanying base prospectus. The second part, theaccompanying base prospectus, gives more general information, some of which may not apply to this offering. You should read both this Before buying any of the common stock that we are offering, we urge you to carefully read this prospectus supplement, togetherwith the accompanying base prospectus and the information incorporated by reference as described under the headings “Where You CanFind More Information” and “Incorporation of Certain Information by Reference” in this prospectus supplement. These documents contain This prospectus supplement contains or incorporates by reference summaries of certain provisions contained in some of thedocuments described herein, but all such summaries are qualified in their entirety by the actual documents. Copies of some of thedocuments referred to herein have been or will be filed or have been or will be incorporated by reference as exhibits to the registration This prospectus supplement describes the terms of this offering of common stock and also adds to and updates informationcontained in the documents incorporated by reference into this prospectus supplement and the accompanying base prospectus. To theextent there is a conflict between the informat